This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
20


nanotimes


Companies Facts


ment for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystalliza- tion and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug meta- bolism and pharmacokinetics services.


A http://www.amriglobal.com


pany Antisense Pharma presented current data from its ongoing clinical Phase I/II trial with intrave- nous monotherapy of trabedersen (AP 12009) for the treatment of patients with advanced pancreatic cancer (PanCa), malignant melanoma (MM), and colorectal carcinoma (CRC). During the oral presen- tation session ‘Developmental Therapeutics – Clinical Pharmacology and Immunotherapy’ Helmut Oettle, MD, PhD, Charité Medical Faculty of the Humboldt University of Berlin, coordinating investigator pointed out trabedersen’s encouraging safety and efficacy data: “These data suggest that trabedersen is safe and very well tolerated in systemic application – and quality of life is already a crucial factor in validation of new anti cancer drugs.” PanCa patients treated 2 nd-line with trabedersen (N=15) reached a median overall survival (mOS) of 6.9 months which is com- parable to best available chemotherapy (mOS 5 – 6 months, historical data) 1. Additionally, patients treated 2nd-line with the dose 140 mg/m2/d (N=9) showed an encouraging survival benefit: their mOS was 13.4 months – in comparison to best available chemotherapy.


A


t the international cancer congress ASCO 2011 in Chicago, USA, the biopharmaceutical com-


MRI (NASDAQ: AMRI) and Proteros Biostruc- tures GmbH (Proteros) have signed an agree-


“Since there is no approved 2nd-line treatment for PanCa patients in the USA and Europe, we are con- fident that our innovative immunostimulatory me- dication trabedersen will help to prolong survival in advanced pancreatic cancer patients.” adds Hubert Heinrichs, MD, PhD, Chief Medical Officer at Anti- sense Pharma.


http://www.antisense-pharma.com http://chicago2011.asco.org/Home.aspx http://abstract.asco.org/AbstView_102_74007.html


Commission for a proposed initial public offering of its common stock. Goldman, Sachs & Co. and Mor- gan Stanley & Co. LLC will act as joint book-running managers for the offering. The number of shares to be sold in the proposed offering and the price range of the proposed offering have not yet been deter- mined.


A


In October 2011, BASF Venture Capital, Germany, has led a $21.5 million round of investment in Aspen Aerogels, Inc. Aspen supplies reinforced, nanopo- rous aerogel insulation products that are up to five times more effective than other insulation mate- rials. The company‘s solutions enable customers to conserve energy in a variety of industries including building and construction, chemicals, transportation and oil and gas.


Other investors are RockPort Capital, Tenaya Ca- pital, Reservoir Capital Group, Arcapita Ventures


spen Aerogels, Inc., has filed a registration statement with the Securities and Exchange


11-06/07 :: June/July 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111